ASND
HOLD / NEUTRALMeanRevComposite
59.20
Technical
63.10
Fundamental
57.90
Rank
—
Price
259.62
Hurst
-0.11
As of
Aug 20, 2026
Daily
Ascendis Pharma A/S
HealthcareBiotechnologyAscendis Pharma is a biopharmaceutical firm headquartered in Denmark that develops treatments using its TransCon technology platform for rare endocrine and oncology conditions across global markets. The company currently markets SKYTROFA, a therapy for children with growth hormone deficiency, and YORVIPATH, a daily injection for adults with chronic hypoparathyroidism, while advancing additional endocrinology candidates and oncology programs through clinical trials.
Market cap
$15.7B
P/E (trailing)
19.15
P/E (forward)
21.60
PEG ratio
—
Dividend yield
—
Beta
—
52w range
186.05 – 282.15
Return on equity
+118.78%
Profit margin
+70.84%
Revenue growth
+114.70%
Earnings growth
—
Price history
1Y: 239.04 (+19.9%) · range 189.74–277.18
Cycle position
54/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 13 · NOT READY · exit proximity 0
Conviction
32/ 100 · maturity 100%
VScore.4017
Buildup.2065
EMA entry setup.2513
Fundamentals.1558
Volume profile
POC
240.62
Price vs POC
-0.7%
Overhead supply
60%
Runway
+0.0%
Value area 221.04–261.78 · 60% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| short-interest | 0.093 | Aug 31, 2026 |
| earnings-surprise | 0.033 | Sep 11, 2026 |
| trend-signal | 0.000 | Sep 1, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +3.42% | +6.40% | 15/20d |
| 40d | +3.42% | +6.40% | 15/40d |